Journal Logo

PARTIAL RESPONSE OR BETTER AT 6 MONTHS IS PROGNOSTIC OF PROGRESSION-FREE SURVIVAL IN PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB

PF485

Castillo, J.1; Abeykoon, J.2; Gustine, J.1; Zanwar, S.2; Keezer, A.1; Meid, K.1; Dubeau, T.1; Xu, L.1; Yang, G.1; Hunter, Z.1; Advani, R.3; Ansell, S.2; Gertz, M.2; Kapoor, P.2; Palomba, L.4; Treon, S.1

doi: 10.1097/01.HS9.0000560240.75742.9f
Poster Session I: Indolent and mantle-cell non-Hodgkin lymphoma - Clinical
Free

1Dana-Farber Cancer Institute, Boston

2Mayo Clinic, Rochester

3Stanford Cancer Center, Stanford

4Memoral Sloan Kettering Cancer Center, New York, United States

Back to Top | Article Outline

Background:

Ibrutinib is approved in Europe and the US for the treatment of Waldenstrom macroglobulinemia (WM) with a median progression-free survival (PFS) measured on several years. As PFS is commonly used for drug approval by regulatory entities, there is an unmet need of reliable surrogate markers for PFS that could help accelerating such process. This is of importance with novel BTK inhibitors currently in clinical trials.

Back to Top | Article Outline

Aims:

We hypothesized that the depth of response at 6 months can be predictive of PFS in patients with WM treated with the BTK inhibitor ibrutinib.

Back to Top | Article Outline

Methods:

We evaluated our hypothesis in two separate cohorts of WM patients treated with ibrutinib. The learning cohort was composed by participants of two prospective clinical trials at Dana-Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center and Stanford Cancer Center. The validation cohort was composed by consecutive WM patients treated with ibrutinib off clinical trial at DFCI and Mayo Clinic. Categorical responses at 6 months were assessed based on criteria from the 6thInternational Workshop for WM. PFS6 was defined as the time from the 6-month response assessment until progression of disease or death from any cause. PFS6 curves were generated using the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazard regression models were fitted for PFS6. Pvalues <0.05 were considered statistically significant.

Back to Top | Article Outline

Results:

The learning and validation cohorts were composed by 92 and 190 WM patients treated with ibrutinib, repsectively. There were no statistical differences between cohorts with regards to age, sex, serum IgM level, hemoglobin level, bone marrow involvement, prior treatment status, and MYD88 and CXCR4 mutational status (p>0.05 for all variables). The rates of partial response (PR) or better at 6 months in the learning and validation cohorts were 63% (54/86) and 72% (114/159), respectively (p = 0.15). The median PFS6 was not reached in the learning cohort and was 53 months (95% CI 44-not reached) in the validation cohort. In the learning cohort, the median PFS6 for patients who attained a PR or better at 6 months was not reached, while for the patients who did not attained PR at 6 months was 48 months (95% CI 33-not reached). The 3-year PFS rate for patients who attained a PR or better at 6 months was 83% (95% CI 68-91%), while for patients who did not attained PR at 6 months was 58% (95% CI 33-76%) (Figure, left, log-rank p = 0.02). Attaining PR or better at 6 months was associated with a hazard ratio (HR) or progressing or dying of 0.37 (95% CI 0.16-0.87; p = 0.02).In the validation cohort, the median PFS6 for patients who attained a PR or better at 6 months was 53 months (95% CI 44-not reached), while for the patients who did not attained PR at 6 months was 32 months (95% CI 22-not reached). The 3-year PFS rate for patients who attained a PR or better at 6 months was 79% (95% CI 67-87%), while for patients who did not attained PR at 6 months was 50% (95% CI 26-70%) (Figure, right, log-rank p = 0.04). Attaining PR or better at 6 months was associated with a hazard ratio (HR) or progressing or dying of 0.46 (95% CI 0.22-0.98; p = 0.04). Age, sex, serum IgM level, hemoglobin level, bone marrow involvement and prior treatment status were not prognostic of PFS6 in both cohorts.

Figure

Figure

Back to Top | Article Outline

Summary/Conclusion:

Attaining a PR or better at 6 months to ibrutinib is associated with longer median PFS and higher rates of 3-year PFS in WM patients. Depth of response at 6 months could serve as a surrogate for PFS in clinical trials evaluating BTK inhibitors in WM patients.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.